World's Best Scientists 2026 revealed!
Award Badge
Microbiology
Italy
2026

D-Index & Metrics

Microbiology

D-Index
96
Citations
38455
World Ranking
497
National Ranking
7

Medicine

D-Index
98
Citations
44067
World Ranking
8811
National Ranking
300

Research.com Recognitions

  • 2026 - Research.com Microbiology in Italy Leader Award
  • 2025 - Research.com Microbiology in Italy Leader Award
  • 2023 - Research.com Microbiology in Italy Leader Award
  • 2022 - Research.com Microbiology in Italy Leader Award

Overview

Andrea Antinori is affiliated with the Catholic University of the Sacred Heart in Italy. Their research primarily spans the field of medicine, with a focus on infectious diseases, virology, epidemiology, neurology, and molecular biology.

The scientist's work is notably concentrated on topics such as COVID-19 clinical research studies, SARS-CoV-2 and COVID-19 research, HIV research and treatment, HIV/AIDS drug development and treatment, HIV/AIDS research and interventions, long-term effects of COVID-19, and poxvirus research and outbreaks.

Recent papers authored or coauthored by Andrea Antinori include:

  • Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022 (2022, New England Journal of Medicine)
  • Epidemiological, clinical and virological characteristics of four cases of monkeypox support transmission through sexual contact, Italy, May 2022 (2022, Eurosurveillance)
  • ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population (2020, European Journal of Human Genetics)
  • Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19) (2020, Cell Death and Differentiation)
  • Monkeypox virus isolation from a semen sample collected in the early phase of infection in a patient with prolonged seminal viral shedding (2022, The Lancet Infectious Diseases)

Andrea Antinori frequently collaborates with several co-authors, including:

  • Enrico Girardi
  • Valentina Mazzotta
  • Alessandra Vergori
  • Emanuele Nicastri
  • Roberta Gagliardini

The most common venues where their work is published include:

  • International Journal of Infectious Diseases
  • Viruses
  • Journal of Antimicrobial Chemotherapy
  • Journal of Medical Virology
  • Vaccines

Best Publications

  • Updated research nosology for HIV-associated neurocognitive disorders

    A. Antinori;G. Arendt;J. T. Becker;B. J. Brew

  • Mapping the human genetic architecture of COVID-19

    Unknown

  • Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

    Alison J Rodger;Valentina Cambiano;Tina Bruun;Pietro Vernazza

  • Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients.

    A d'Arminio Monforte;A C Lepri;G Rezza;P Pezzotti

  • Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection.

    Adriana Ammassari;Rita Murri;Patrizio Pezzotti;Maria Paola Trotta

  • Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature.

    Adriana Ammassari;Maria Paola Trotta;Rita Murri;Francesco Castelli

  • Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

    Bonaventura Clotet;Judith Feinberg;Jan Van Lunzen;Marie Aude Khuong-Josses

  • Late presentation of HIV infection: a consensus definition

    A Antinori;T Coenen;D Costagiola;N Dedes

  • Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study

    Linda Wittkop;Huldrych F Günthard;Frank de Wolf;David Dunn

  • Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

    Paul E. Sax;Anton Pozniak;M. Luisa Montes;Ellen Koenig

  • Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

    Unknown

  • Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors.

    Valerio Tozzi;Pietro Balestra;Rita Bellagamba;Angela Corpolongo

  • Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons.

    Adriana Ammassari;Andrea Antinori;Maria Stella Aloisi;Maria Paola Trotta

  • Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy.

    Fabrizio Starace;Adriana Ammassari;Maria Paola Trotta;Rita Murri

  • Diagnosis of AIDS-related focal brain lesions A decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF

    Andrea Antinori;A. Ammassari;A. De Luca;A. Cingolani

  • All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration

    Charlotte Lewden;Vincent Bouteloup;Stéphane De Wit

  • CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study

    Cristina Mussini;Patrizia Lorenzini;Alessandro Cozzi-Lepri;Giuseppe Lapadula

  • Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA).

    Antonella Cingolani;Andrea Antinori;Maria Gabriella Rizzo;Rita Murri

  • Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects.

    Andrea De Luca;Roberto Bugarini;Alessandro Cozzi Lepri;Massimo Puoti

  • Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy.

    Andrea Antinori;Antonella Cingolani;Lucia Alba;Adriana Ammassari

  • Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy.

    Krishnan Bhaskaran;Cristina Mussini;Andrea Antinori;Ann Sarah Walker

  • One-pill once-a-day HAART: A simplification strategy that improves adherence and quality of life of HIV-infected subjects

    Monica Airoldi;Mauro Zaccarelli;Luca Bisi;Teresa Bini

Frequent Co-Authors

Antonella d'Arminio Monforte
Antonella d'Arminio Monforte University of Milan
Carlo Federico Perno
Carlo Federico Perno University of Milan
Andrea De Luca
Andrea De Luca University of Siena
Adriana Ammassari
Adriana Ammassari Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
Cristina Mussini
Cristina Mussini University of Modena and Reggio Emilia
Alessandro Cozzi-Lepri
Alessandro Cozzi-Lepri University College London
Francesca Ceccherini-Silberstein
Francesca Ceccherini-Silberstein University of Rome Tor Vergata
Enrico Girardi
Enrico Girardi Austrian Academy of Sciences
Massimo Andreoni
Massimo Andreoni University of Rome Tor Vergata
Giuseppe Ippolito
Giuseppe Ippolito Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in microbiology, exploring related online degrees can expand career opportunities in healthcare and science fields. Many institutions offer shortest online medical billing and coding certificate programs, which provide a quick pathway to entering the medical administration sector.

Beyond microbiology, there are numerous online healthcare degrees that allow learners to specialize in areas like public health, nursing, and health informatics. These programs offer flexibility for working professionals seeking to advance their qualifications.

For those interested in advancing into public health, several mph online programs with easy admission requirements offer accessible routes to earn a Master of Public Health degree without stringent entry criteria. This can complement a microbiology background by focusing on disease prevention and health policy.

Career options also include roles such as a child life specialist, where individuals with a Bachelor’s degree can enter a rewarding healthcare profession. Learn more about the child life specialist salary with bachelor degree and what to expect in this growing field.

Best Scientists Citing Andrea Antinori

Trending Scientists